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Abstract 
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that regulates gene expression in response to 
hypoxia, and has been associated with athletic performance. The aims of this study were 1) to determine 
the frequency distribution of HIF1A Pro582Ser (rs11549465) polymorphism among 155 Israeli athletes 
(sprinters and endurance athletes) and 240 healthy controls and 2) to analyze the influence of the 
interaction between HIF1A Pro582Ser and ACTN3 R577X (rs1815739) genotypes on sprint 
performance. There were no differences across the HIF1A genotype and allele frequencies among 
endurance athletes, sprinters and controls. Similarly, no differences were found between the subgroups 
of top-level and national-level endurance athletes, or between top-level and national-level sprinters. 
Conversely, interaction effects were found between HIF1A Pro582Ser and ACTN3 R577X 
polymorphisms and sprinters. The proportion of HIF1A Pro/Pro + ACTN3 R/R genotypes was 
significantly higher in sprinters than in endurance athletes and healthy controls (P=0.002).  In addition, 
the odds ratio for HIF1A Pro/Pro + ACTN3 R/R genotype carriers being a sprinter was 2.25 (95% 
confidence interval 1.24-4.1), and for HIF1A Pro/Pro + ACTN3 R/R genotype carriers being an 
endurance athlete was 0.5 (95% confidence interval 0.2-1.24). We conclude that HIF1A Pro582Ser 
polymorphism by itself is not critical in determining sprint performance. However, sprinter performance 
is determined by the interaction between the wild-type HIF1A Pro/Pro genotype and ACTN3 RR 
genotype. 
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Introduction 
Favorable genetic endowment together with environmental factors seem to be necessary for attaining 
the highest level of athletic performance. Although sprint performance is likely a polygenic trait, only a 
few single nucleotide polymorphisms (SNP's), namely ACTN3 R577X [1-4], ACE I/D [5-7] and more 
recently eNOS -786 T/C [8] and, IL-6 -174G/C ( ), were found to be associated with sprint 
performance.  
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that is unique among mammalian 
transcription factors with respect to the demonstrated specificity and sensitivity of its induction by 
hypoxia [9]. HIF-1 is part of a family of heterodynamic basic helix-loop-helix (bHLH) proteins, which 
is composed of two subunits, HIF-1 α and HIF-1 β. Expression levels of the HIF-1α subunit is precisely 
regulated by cellular O2 concentration such that levels of HIF-1α protein and HIF-1 DNA-binding 
activity increases exponentially as O2 concentration decreases [10]. The α subunit of HIF1 also 
promotes cell survival and angiogenesis, and was suggested to influence glucose metabolism [11]. In 
connecting these data to muscle function, HIF-1 α mRNA and protein levels were found to be 
constitutively higher in type IIX muscle fibers, which have a high fatigability compared with the more 
oxidative type 1 muscle fibers, which have a low fatigability [12] 
A functional SNP was identified in the HIF1A gene which encodes the α subunit of HIF1 protein, 
resulting in the replacement of proline (Pro) with serine (Ser) at amino-acid 582 [13]. The rare Ser582 
allele, rather that the wild type Pro582 allele, was previously associated with increased transcription 
activity and stability of HIF1A protein. Ahmetov et al [14] have recently found that carriers of the 
Pro/Ser genotype had a significantly higher percentage of type IIX muscle fibers than homozygous for 
the Pro582 allele. Therefore, the Ser582 allele may increase the hypoxic resistance of cells, which 
would result in high glycolytic potentialities [15].  
Since sprint performance requires a large amount of fast-twitch type IIX muscle fibers (Spencer MR & 
Gastin PB (2001). Energy system contribution during 200- to 1500-m running in highly trained athletes, 
it can be assumed that the proportion of the Ser582 allele will be higher among sprinters compared to 
endurance athletes and sedentary controls. Therefore, the purposes of the present study were 1) to 
compare the frequency distribution of the HIF1A Pro582Ser (rs11549465)  polymorphism between 
athletes of sports with different demands (endurance vs. sprinters) as well as between athletes of 
competitive levels (elite-level vs. national-level), and 2) to test the influence of the interaction between 
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the HIF1A Pro582Ser and the ACTN3 R577X (rs1815739) genotypes, since the ACTN3 R577X 
polymorphism was previously reported to influence power-oriented top-level athletic performance in a 
broad variety of ethnic groups [1-4].  
Methods    
Subjects 
 The study followed recent recommendations for replicating genotype-phenotype association studies 
[16]. Owing to limitations, genotyping was not performed in two independent laboratories using 
different methodology. One hundred and fifty-five track and field athletes (119 men and 36 women, 
age=35.9+12.2 yrs) volunteered to participate in the study. Athletes were included in the study sample 
only if they had participated in national/international track and field championships. The control group 
consisted of 240 non-athletic healthy individuals who were randomly selected from the Israeli 
population. Controls were not engaged in physical activity on a regular basis. Athletes were divided into 
two groups: 1) An endurance-type group that included 74 long distance runners whose main events 
were the 10000m run and the marathon; 2) A sprint-type group that included 81 sprinters whose main 
event was the 100-200m dash. According to their individual best performances, athletes within each 
group were further divided into two subgroups: elite-level (those who had represented Israel in world 
track and field championships or in the Olympic Games) and national-level. All subjects, athletes and 
non-athletes, were Israeli Caucasians for > 3 generations, with an equivalent ratio of mixed Jews 
coming from Arab countries (non-Ashkenazi) and Jews coming from Europe (Ashkenazi) (2:1). The 
study was approved by the Helsinki Committee, the formal ethics committee of the Hillel-Yaffe 
Medical Center, Hadera, Israel, according to the Declaration of Helsinki. A written informed consent 
was obtained from each participant.  
Genotyping 
Genomic DNA was extracted from peripheral EDTA treated anti-coagulated blood using a standard 
protocol. Genotyping of the HIF1A Pro582Ser (rs11549465) polymorphism was performed using 
polymerase chain reaction (PCR). The resulting PCR products were genotyped (in the Genetics and 
Molecular Biology Laboratory of the Zinman College of Physical Education and Sport Sciences at the 
Wingate Institute, Netanya, Israel) by restriction fragment length polymorphism (RFLP). Briefly, a 197-
bp fragment of HIF1A Pro582Ser (C/T) was amplified by PCR using primers F 5'- 
GACTTTGAGTTTCACTTGTTT -3' and R 5'- ACTTGCGCTTTCAGGGCTTGCGGAACTGCTT -3'. 
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PCR was performed
 
by first denaturation  at 94°C for 5 min,  30 34 cycles of denaturation at 94°C for 
30 60s, annealing
 
at 62 55°C for 30 60 s, extension at 72°C for 3 1 min, and
 
a final extension step of 7 
10 min at 72°C. The amplified fragment
 
subsequently underwent digestion by Tsp451 (New England 
Biolabs,
 
Beverly, MA, USA) in a condition recommended by the supplier. The
 
digested products were 
then electrophoresed in a 3% agarose
 
gel. This method yields a 197-bp fragment in the presence of the T 
(Ser) allele, and 154 and 43 bp in the presence of the C (Pro) allele. 
 The ACTN3 R577X polymorphism was genotyped according to a previously reported method [2]. To 
ensure proper internal control, for each genotype analysis we used positive and negative controls from 
different DNA aliquots that were previously genotyped by the same method, according to recent 
recommendations for replicating genotype-phenotype association studies [16]. The RFLP results were 
scored by two experienced and independent investigators who were blind to the subject data. 
Data analysis  
The SPSS statistical package, version 15.0, was used to perform all statistical evaluations (SPSS Inc., 
Chicago, IL, USA). Allele frequencies were determined by gene counting. A Pearson χ2 test, Yates 
corrected χ2 test, or Fischer exact test was used to confirm that the observed genotype frequencies were 
in Hardy-Weinberg equilibrium, and to compare the HIF1A Pro582Ser alleles and genotype frequencies 
between athletes and control subjects. One of these tests was also used to examine the interaction 
between the HIF1A Pro582Ser and the ACTN3 R577X genotypes in relation to sprint performance, and 
in relation to the sprinter's level of performance. A logistic regression analysis was set in order to 
calculate the odds ratio for the interaction of both polymorphisms in sprint athletes and in control 
subjects. The level of significance was set at P < 0.05. 
 
Results 
The complete data on allele and genotype frequencies of the HIF1A Pro582Ser polymorphism are 
shown in Table 1. The genotype subtype did not differ by gender in the athletes group (χ2 = 0.7, d.f=2, 
P=0.71) or in the control group (χ2 = 1.88, d.f=2, P=0.39). Since the Israeli population includes 
Caucasians who are mixed non-Ashkenazi and Ashkenazi, we confirmed that there was an equivalent 
ratio of non-Ashkenazi and Ashkenazi descent in each group (2:1), and that there were no differences 
across HIF1A genotype between non-Ashkenazi and Ashkenazi descendants (χ2 = 0.07, d.f=2, P=0.9). 
HIF1A genotype distribution was in agreement with the Hardy-Weinberg equilibrium within the 
6 
 
endurance athletes (P=0.33), the sprinters (P=0.9), and the control group (P=0.64). Genotype 
distribution and allele frequencies were similar in the groups of endurance athletes, sprinters and 
controls (Table 1). Similarly, no statistical differences were found between the subgroups of top-level 
endurance athletes and national-level endurance athletes, or between top-level and national-level 
sprinters (Table 2). However, interaction effects were found between HIF1A Pro582Ser and ACTN3 
R577X polymorphisms and sprinters (see Table 3). HIF1A Pro/Pro + ACTN3 R/R genotypes were more 
frequently found in the sprinters than in the control group (see Figure 1). 
In the whole cohort of athletes, the odds ratio of HIF1A Pro/Pro + ACTN3 R/R genotypes being a 
sprinter was 2.25 (95% confidence interval 1.24-4.1) and the HIF1A Pro/Pro + ACTN3 R/R genotypes 
being an endurance athlete 0.5 (95% confidence interval 0.2-1.24). 
 
Discussion 
In the present study we investigated the association between HIF1A Pro582Ser polymorphism and elite 
athletic performance. The HIF1A gene was chosen as a genetic marker of athletic ability due to its 
proposed role in increasing transcription activity [13], promoting a shift of type I (oxidative) muscle 
fibers to type IIX (glycolitic) muscle fibers [14] and increasing hypoxic resistance of cells [15]. Our 
main findings were 1) genotype distribution and allele frequency within the HIF1A Pro582Ser 
polymorphism was similar in endurance athletes, sprinters and sedentary controls, and 2) HIF1A 
Pro/Pro + ACTN3 R/R genotypes were more frequently found in the sprinters than in the endurance 
athletes group and the control group. These findings suggest that the HIF1A Pro582Ser polymorphism 
by itself is not a factor in determining power/sprint performance. However, the wild-type HIF1A 
Pro/Pro genotype interacts with the ACTN3 RR genotype, which was previously associated with 
power/sprint performance [1-4].  
HIF-1 mediates increased glycolytic generation of ATP and possibly other intracellular metabolic 
adaptations to hypoxia  [11]. Thus, one can expect that this protein will play a role in sprint events, 
since short distance sprint and power events rely largely on the anaerobic pathways, which are 
especially dependent on intramuscular stored CP, ATP and glycogen (Spencer & Gastin, 2001). 
Reports regarding the interaction between the HIF1A Pro582Ser polymorphism and the HIF1A 
transcriptional activity are limited as well as inconsistent. The Ser582 allele was associated with higher 
transcription activity among head and neck squamous cell carcinoma (HNSCC) patients [15]. However, 
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another study suggested the opposite. An in vitro reporter gene transfection experiments confirmed that 
homozygous for the Ser582 allele have lower transcriptional activity than wild-type alleles at 
comparable expression levels [17]. Furthermore, the Ser582 allele by itself also had significantly 
decreased reporter gene activity at some of the concentrations, although results were less consistent than 
with the double mutant [17]. The cross-sectional comparison in this study revealed that a higher 
proportion of people showing a specific “preferred genotype” ( e.g. HIF1A Pro/Pro + ACTN3 R/R ) 
were more likely to be sprinters, and thus it can be assumed that the power/sprint athletes will have 
higher transcription activity of the HIF1A gene which results in high glycolytic potentialities.  
The results of the present study are not in agreement with the results of Ahmetov et al. [14], who 
suggested that the incidence of HIF1A Ser582 allele was significantly higher in weight-lifters than in 
controls. However, almost 29% of the sprinters in the present study harbored the Pro/Pro+ R/R 
genotype as opposed to only 8% and 15% in the endurance athlete group and the control group, 
respectively. This emphasizes the important role of the functional ACTN3 R/X polymorphism in 
power/sprint performance, since it is well established that actinin-3 in these athletes is presented in 
higher amounts in the RR genotype than in other genotypes [4], and  may be necessary for developing 
forceful contractions at high velocity [18].  
The results of the present study also emphasize the assumption that many other yet-to-be-identified 
polymorphisms, which may not influence sports performance individually per se, could play an 
important role when combined with other variants. Furthermore, beyond genotype-phenotype 
associations, the effect of short, non-coding RNA molecules, namely MicroRNAs (miRNAs), on human 
muscle phenotypes remains to be determined. It is now believed that MicroRNAs regulate skeletal 
muscle post-transcriptional gene expression, and thus modulate important aspects of muscle function, 
including muscle contractility [19].  
Our study was not without limitations. The group of elite athletes was relatively small, owing to the 
small number of available athletes. Nevertheless, it consisted of highly-selected endurance and sprint 
athletes having a unique phenotype. Also, genetic association studies must always be interpreted with 
caution.  As with any statistical analysis, there is a non-trivial possibility of a false positive result [20].  
In conclusion, the HIF1A Pro582Ser polymorphism is not associated with sprint performance. However, 
the HIF1A Pro/Pro + ACTN3 R/R genotypes were more frequently found in the sprinters than in the 
endurance athletes group and the control group. Further investigations are needed to clarify the possible 
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role of other polymorphisms and the combination of polymorphisms in determining athletic 
performance. 
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Tables: 
 
Table 1. Genotype and allele frequencies of HIF1A Pro582Ser polymorphism in all groups  
 
 
  Genotype    Allele frequencies  
Athlete groups n Pro/Pro Pro/Ser Ser/Ser Allele Pro Allele Ser 
       
Endurance  74 53 (72) 21(28) 0 (0) 127 (0.86) 21 (0.14) 
Sprinters 81 59 (73) 20 (25) 2 (2) 138 (0.85) 24 (0.15) 
Control 240 173 (72) 63 (26) 4 (2) 409 (0.85) 71 (0.15) 
 
 
Data is absolute and relative values (within parentheses)
  
 χ2 = 1.85, d.f=2, P=0.76 for overall differences in genotype frequencies  
 χ2 = 0.04, d.f=1, P=0.98 for overall differences in allele frequency 
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Table 2. The HIF1A Pro582Ser genotype and allele frequencies in sprinters and endurance athletes 
according to their level of competition.  
 
 
      Genotype     Allele frequencies 
Athlete groups Competitive n Pro/Pro Pro/Ser Ser/Ser Allele Pro Allele Ser 
   level       
Endurance Top-level 20 16 (80) 4 (20) 0 (0) 36 (0.9) 4 (0.1) 
 National level 54 37 (69) 17 (31) 0 (0) 91(0.84) 17 (0.16) 
Sprinters Top-level 26 20 (77) 6 (23) 0 (0) 46 (0.88) 6 (0.12) 
  National level 55 39 (71) 14 (25) 2 (4) 92 (0.84) 18 (0.16) 
 
Data is presented as absolute and relative values (within parentheses)  
 
χ2 = 1.07, d.f=2, P=0.58 for genotype frequencies in top-level vs. national level sprinters 
χ2 = 0.65, d.f=1, P=0.42 for allele frequency in top-level vs. national level sprinters 
χ2 = 0.95, d.f=2, P=0.33 for genotype frequencies in top-level vs. national level endurance athletes 
χ2 = 0.79, d.f=1, P=0.37 for allele frequency in top-level vs. national level endurance athletes 
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Table 3. Combined ACTN3 R577X and HIF1A Pro582Ser polymorphisms genotype frequencies within 
the endurance athletes, the sprinters, and the control group. 
 
 
ACTN3 Genotype HIF1A genotype Endurance athletes Sprinters Controls 
    (n=74) (n=81) (n=240) 
RR Pro/Pro 6 (8.1) 23 (28.4) 36 (15) 
RR Pro/Ser 8 (10.8) 9 (11.1) 13 (5.4) 
RX Pro/Pro 30 (40.5) 23 (28.4) 104 (43.3) 
RX Pro/Ser 6 (8.1) 7 (8.6) 42 (17.5) 
RX Ser/Ser 0 (0) 2 (2.5) 3 (1.3) 
XX Pro/Pro 17 (23) 13 (16) 33 (13.8) 
XX Pro/Ser 7 (9.5) 4 (4.9) 8 (3.3) 
XX Ser/Ser 0 (0) 0 (0) 1 (4) 
 
Data is presented as absolute and relative values (within parentheses)  
χ2 = 33.3, d.f=14, P=0.003 for overall combined genotype distribution 
χ2 = 12.4, d.f=2, P = 0.002 for RR+Pro/Pro  
χ2 = 2.3, d.f=2, P = 0.33 for RR+Pro/Ser 
χ2 = 3.4, d.f=2, P = 0.19 for RX+Pro/Pro 
χ2 = 4.9, d.f=2, P = 0.08 for RX+Pro/Ser 
χ2 = 2.5, d.f=2, P = 0.29 for RX+Ser/Ser 
χ2 = 2.6, d.f=2, P = 0.27 for XX+Pro/Pro 
χ2 =3.5, d.f=2, P = 0.17 for XX+Pro/Ser 
χ2 =3.5, d.f=2, P = 0.17 for XX+Pro/Ser 
χ2 =8.0, d.f=2, P = 0.02 for XX+Ser/Ser 
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Figure legends: 
 
Figure 1. Genotype frequencies of the "optimal genotype" for power/sprint phenotypes within the 
sprinters, the endurance athletes, and the control group. 
 
χ2 = 12.5, d.f=2, P=0.002 for genotype frequencies differences in ACTN3 RR+HIF1A Pro/Pro vs. other 
genotypes between endurance athletes, sprinters, and controls. 
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Figure 2. Genotype frequencies of the "optimal genotype" for power/sprint phenotypes stratified by 
gender within the sprinters group. 
 
χ2 = 0.18, d.f=1, P=0.78 for genotype frequencies differences in ACTN3 RR+HIF1A Pro/Pro vs. other 
genotypes between male and female. 
 
 
